SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Reata Pharmaceuticals, Inc. (RETA) .
本页证实的标准:
- VALUE (10/100, 未通过) — 分析师共识目标价暗示当前价格存在下行风险 ($62.67, 63.6%).
- 分析师共识目标价 $62.67 (-63.6% 下行风险) — 分析师认为当前价格水平存在明显下行风险。
SharesGrow 综合评分： 23/100 其中 0/7 项标准通过。
SharesGrow 7-Criteria Score
✗
价值
10/100
Price-to-Earnings & upside
Proven by this page
~
健康
50/100
Debt-to-Equity & liquidity
→ Health
估值概览 — RETA
估值倍数
P/E (TTM)0.0
前瞻 P/EN/A
PEG 比率N/A
前瞻 PEGN/A
P/B 比率0.00
P/S 比率2,825.07
EV/EBITDA0.0
每股数据
EPS (TTM)$-8.59
每股账面价值$0.00
每股营收$0.06
每股自由现金流$0.00
收益率与内在价值
盈利收益率N/A
股息收益率0.00%
分析师目标价$62.67 (-63.6%)
P/E Ratio & Earnings Yield
每股收益 (EPS) 历史
| Year |
EPS（稀释） |
营收 |
净利润 |
净利润率 |
| 2013 |
$-1.76 |
$51.2M |
$-35.11M |
-68.6% |
| 2014 |
$0.03 |
$51.95M |
$689K |
1.3% |
| 2015 |
$-0.26 |
$50.32M |
$-1.45M |
-2.9% |
| 2016 |
$-0.31 |
$49.86M |
$-6.23M |
-12.5% |
| 2017 |
$-1.99 |
$48.06M |
$-47.67M |
-99.2% |
| 2018 |
$-2.91 |
$53.59M |
$-80.55M |
-150.3% |
| 2019 |
$-9.54 |
$26.52M |
$-290.17M |
-1094.3% |
| 2020 |
$-7.35 |
$9.02M |
$-247.75M |
-2747% |
| 2021 |
$-8.19 |
$11.49M |
$-297.39M |
-2588.2% |
| 2022 |
$-8.59 |
$2.22M |
$-311.9M |
-14075% |
